Table 2.
Top Networks identified in circulating lymphocytes and monocytes by Ingenuity Pathway Analysis (IPA) in each pairwise comparison of the patients groups.
Pairwise comparison | Associated Network Functions | Score |
---|---|---|
T2DMpoorly-DL-P versus H | Cell Cycle, Cell-To-Cell Signaling and Interaction, Hematological System Development and Function | 33 |
Cellular Movement, Immune Cell Trafficking, Connective Tissue Disorders | 31 | |
Antimicrobial Response, Inflammatory Response, Dermatological Diseases and Conditions | 31 | |
Cellular Movement, Cellular Development, Cellular Growth and Proliferation | 31 | |
Cellular Movement, Cancer, Organismal Injury and Abnormalities | 29 | |
T2DMwell-DL-P versus H | Cellular Movement, Immune Cell Trafficking, Cell-mediated Immune Response | 37 |
Infectious Diseases, Immunological Disease, Connective Tissue Disorders | 33 | |
Hematological System Development and Function, Tissue Morphology, Cell-To-Cell Signaling and Interaction | 33 | |
Cardiovascular System Development and Function, Tissue Morphology, Digestive System Development and Function | 29 | |
Cell Death and Survival, Inflammatory Response, Organismal Injury and Abnormalities | 27 | |
DL-P versus H | Cellular Movement, Immune Cell Trafficking, Cell-To-Cell Signaling and Interaction | 37 |
Cellular Assembly and Organization, Cancer, Organismal Injury and Abnormalities | 33 | |
Dermatological Diseases and Conditions, Developmental Disorder, Hereditary Disorder | 33 | |
Cell-To-Cell Signaling and Interaction, Cell Morphology, Cellular Movement | 31 | |
Organismal Development, Cardiovascular System Development and Function, Hematological System Development and Function | 20 | |
P versus H | Cell Death and Survival, Cell Signaling, Post-Translational Modification | 34 |
Dermatological Diseases and Conditions, Organismal Injury and Abnormalities, Cancer | 34 | |
Inflammatory Disease, Inflammatory Response, Organismal Injury and Abnormalities | 28 | |
Cardiac Arrhythmia, Cardiovascular Disease, Organismal Injury and Abnormalities | 28 | |
Cellular Compromise, Inflammatory Response, Infectious Diseases | 23 |